Skip to content Skip to footer
Sanofi’s latest Dupixent win and Eupraxia Pharmaceuticals’ quiet grind in eosinophilic esophagitis (“EoE”) still tell a coherent, investor‑friendly story: the type 2 inflammation boom is alive, and there is room on the highway for both mega‑cap platforms and focused innovators. For investors,…
Butterfly Network’s (BFLY) Midjourney cameo now sits inside a bigger, more nuanced script: AI‑driven imaging that can delight investors, unnerve ethicists, and occasionally confuse radiologists—all while telehealth platforms like Amwell (AMWL) quietly wire the whole thing into everyday care. The result is…